Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome
Open Access
- 8 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (4) , 1033-1042
Abstract
Currently, there is no effective treatment for adult-onset immunodeficiency (AOID) syndrome with anti-interferon-gamma autoantibodies (anti-IFN-γ-auto-Abs). This study aimed to investigate the effectiveness of bortezomib (BTZ) for decreasing anti-IFN-γ-auto-Abs. A pre- and post-intervention study was conducted from February 2017 through June 2019 at Siriraj Hospital (Bangkok, Thailand). Five patients were invited to receive once-weekly BTZ (1.3 mg/m2 body surface area) subcutaneously for 8 weeks followed by oral cyclophosphamide (1 mg/kg/d) for 4 months. The primary outcomes were the difference in antibody level at 8 and 48 weeks compared with baseline and the incidence of serious adverse events (AEs). The secondary outcome was the occurrence of opportunistic infections (OIs) during the 72 weeks after starting BTZ. The median patient age was 46 years (range, 34–53). All patients had 3–5 OIs prior to enrollment. All patients were receiving antimycobacterial agents for treatment of nontuberculous mycobacterial infection at enrollment. There was no significant difference in the mean optical density of auto-Abs at 8 weeks (3.73 ± 0.72) or 48 weeks (3.74 ± 0.53) compared with baseline (3.84 ± 0.49; P = .336 and P = .555, respectively). However, after serum dilution, the antibody titer nonsignificantly decreased 8–16 weeks after BTZ initiation (P = .345). Ten OIs were observed 24–72 weeks after BTZ initiation. Treatment with BTZ followed by cyclophosphamide yielded no significant decrease in antibody titer levels, and 10 OIs were observed during 24–72 weeks of BTZ treatment. No serious AEs were observed. Combining rituximab with BTZ is likely necessary to prevent generation of new autoantibody-producing plasma cells. Clinical Trials Registration. NCT03103555.Keywords
Funding Information
- Health Systems Research Institute (61-049)
This publication has 35 references indexed in Scilit:
- Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Annals of the New York Academy of Sciences, 2012
- Adult-Onset Immunodeficiency in Thailand and TaiwanNew England Journal of Medicine, 2012
- Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infectionBlood, 2012
- Proteasome inhibition for antibody-mediated rejectionCurrent Opinion in Organ Transplantation, 2009
- Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel AgentsClinical Infectious Diseases, 2009
- Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody ProductionAmerican Journal of Transplantation, 2008
- Disseminated Nontuberculous Mycobacterial Infection in Patients Who Are Not Infected with HIV in ThailandClinical Infectious Diseases, 2007
- Approval Summary for Bortezomib for Injection in the Treatment of Multiple MyelomaClinical Cancer Research, 2004
- Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W MiceJournal of Experimental Medicine, 2004
- Immunophenotypic characterization of peripheral T lymphocytes inMycobacterium tuberculosisinfection and diseaseClinical and Experimental Immunology, 2002